These results pointed to the potential application of ABT-199 in ER+ breast cancer treatment, and in a phase I clinical trial comprising 33 ER+, Bcl-2-expressing metastatic breast cancer cases, venetoclax in combination with tamoxifen showed promising results. Here, BCL2 is linked to breast carcinoma.